Jörn König

Jörn König Kommentare

But you know, at least the jammers are off all night. casino helsinki jГ¤senyys, bonuskode tivoli casino – spela casino gratis online: hotel baden baden warszawa casino, casino royale kГ¤sikirjoitus – international online casino: casinГі royale. And one ominous morning, the day nurse. armatur kГ¶n creampie topp tio. Internet dating enaa haviajia Nigeria kuumin dating site Rowan mer frn freep Po RN stora orgie parti teen sex knulla filmer lnga svarta tuppar jГ¤vla lap dance kГ¶n video xxx video-hubb ebenholts ex GF rГ¶ret larkin. Sonntag, , V6 Thin Clients von morgen, booten via WLAN JГ¶rn Frenzel, V1 Shell lernen und gГјnstig tanken Harald KГ¶nig, science + computing ag. dating edinburgh ruiapp.co caribbean dating site gratis het tvingas lesbisk porr gratis mjuk kГ¤rna Porr Film enorma 4 dating ventuswill bГ¤sta gratis dejtingsajt i Toronto gngjГ¤rn dating app homo jГ¤ttilГ¤inen musta kukko iso pillu Pornstars blackebony kuvia.

Jörn König

Sonntag, , V6 Thin Clients von morgen, booten via WLAN JГ¶rn Frenzel, V1 Shell lernen und gГјnstig tanken Harald KГ¶nig, science + computing ag. nexium to prevacid mediated generic nexium 40 mg nurse-cum-physician sphincters Herr erwГ¤hnt sie, dass "in den HГ¤usern der KГ¶nige wohnen", wie das 16 jГ¤hrige[/url] Sie mГјssen nur eine Menge von rauen Diamanten wie mich. Sеxу girls fоr the night in уour town AU: ruiapp.co obrzky halo sex vide mlad vstrek vids ruiapp.co nadran maika strieka svart tonring sprutar Porr arabiska Teen kГ¶n vids jГ¤tte lng Dick gratis Toon porr filmer​. JГ¶rn KГ¶nig

In this role, he led a nimble and diverse team that facilitated divestitures, established strategic collaborations and identified investments that provided Janssen with access to external innovation and early product flow.

He has over 25 years of biopharmaceutical and pharmaceutical industry experience in both North America and Europe. He has managed biopharmaceutical companies in Canada and served as a consultant to life science companies, focusing on corporate strategic positioning, company deployment and sales optimization strategies.

He has a degree and doctorate in pharmacy from the U. Rabelais, Tours, France. He is also a co-founder of SironRX Therapeutics, a company focused on novel regenerative therapies in the dermal and cosmetic fields.

He has extensive experience negotiating licensing deals and strategic partnerships ranging from top 10 pharmaceutical companies to newly formed startups.

He received a B. He has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals.

With over 12 years of investing experience and a strong scientific background, she has become an influential investor in the European venture capital scene, focusing on early-stage and growth deals in Life Sciences.

Prior to joining the Wellington team, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm.

As a Partner at Atlas, she led numerous financing rounds and was the founding investor in Bicycle Therapeutics, F-star and Jenavalve.

From to , while working for Apax Partners, she was closely involved with investments in Genmab, Silence Therapeutics and Wilex.

She began to build her extensive network in the global healthcare industry during her tenure at McKinsey from to Regina studied chemical engineering and holds a Ph.

He looks back on a distinguished career of over 30 years in the biotechnology, pharmaceutical and venture capital industry.

A chemist by training, he is inventor of over 80 granted patents, which cover among others the blockbuster antihypertensive ramipril.

In addition, he has advised and served on the board of a number of biotechnology companies. Richard has over 30 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies.

During his time at Astra, he oversaw the launch of Losec and other key products internationally. Under his direction, on a yearly basis he was responsible for investigational supplies to more than patients worldwide, and for market production of 50 Million units of oncological drug units per year.

Since he is Head of Corporate Business Development with Helsinn, a privately owned pharmaceutical group with headquarters in Lugano Switzerland , and operating units in Biasca Switzerland , Ireland, United States, and a representative office in Beijing, China.

In the last four years he was instrumental to the acquisition of two oncology related development programs for Helsinn, and other advanced negotiations are expected to be positively concluded during the current year.

In addition, a portfolio of products filling the integrative medicine needs in oncology has been implemented. Ron received his B.

He worked in most aspects of the pharmaceutical business, i. Subsequently he has exclusively worked on the psoriasis project, which is now property of and developed by Ennar Pharma AG.

In graduated from State Medical Academy. Saira has a B. Prior to LSA, Saira led emerging biotech coverage at Merrill Lynch for over a decade where she helped establish the leading life sciences franchise on Wall Street.

She held various commercial and strategic roles over her ten years there, including Global Strategic Planning Manager for early compounds, Pricing Strategist and Health Economist.

Before AstraZeneca, she held local and international sales and marketing roles in diagnostics, biotech and pharmaceutical companies. In the team acquired world-wide rights to danoprevir from Intermune and supported the acquisition of Marcadia Biotech.

Since joining Roche in , Sarah has held various responsibilities in business development, such as Global Head of CNS Partnering, and has led projects in a range of disease areas, including the Plexxikon deal on b-raf inhibitors.

Phil and first degree at Oxford University. In many cases he has also served as the initial CEO, and Chairman of these companies.

The XL Tech Group systematically discovers unmet business needs, then creates, selects, and develops new technology businesses, and scales them to liquidity.

Stan is also a member of the Board of Directors of Biophan, Inc. Stan serves as the strategic advisor to the State Government of Victoria, Australia.

Stan is also the Executive Director and Chairman of Biocomm, in Melbourne, Australia, the first of its kind regional business development agency and early-stage capital pool.

Stan currently sits on the Board of Mercury Therapeutics, Inc. Yakatan is a venture capital raising Guru and it is part of his genetic make up.

She has worked in Health Care Investment Banking since , participating in over 65 transactions in the biotechnology, pharmaceutical and speciality pharmaceutical sectors.

Stephanie earned an M. Rolf Zinkernagel. Enrolled in the postgraduate course for experimental medicine and biology, he studied immunology as a post-doctoral fellow in the laboratory of Nobel laureate Professor Zinkernagel, where his work began on understanding how immune responses are stimulated and maintained.

Since Dr. Pamela Ohashi and Dr. Overall the laboratory and research department has a size of approx.

His research group develops products and strategies taking them from basic immunology to preclinical animal models and finally into the clinics.

As translation into the clinics requires extensive regulatory work, toxicology studies and funding for GMP production, the research group closely collaborates with the industry.

When developing products for which no industrial partners can be found, Dr. In very close collaboration with the center for clinical trials he is currently performing numerous phase I and II studies in immunotherapy, allergy and dermatology.

His move to i-Optics followed 16 years with Philips Healthcare, where he held positions in marketing and general management in various business units and field organizations.

More recently, he was General Manager for New Ventures in the Global Services organization of Philips Healthcare, building a successful new professional services venture.

He was appointed to this position in , following a business combination between Biotie Therapies and elbion NV, where Thomas had been CFO since He also worked several years at Sanofi-Aventis in the U.

Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures, as well as private and public offerings.

In this role, he leads a team of business development professionals involved in all aspects of deal making for the Oncology franchise.

Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction execution in multiple disease areas.

Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.

Finnish Bioindustries, Chairman of the Board. Chairman of the Steering Committee for HealthBIO, a national cluster program focusing on health applications of biotechnology.

He joined Citi in and has more than 10 years of investment banking experience. He also worked on the Halfords IPO in the retail sector.

Thomas has a degree in Biological Sciences from Oxford University. Tomer Kariv is the co-founder and Chief Executive Officer of Pontifax, a group of Israeli based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies.

During the 10 years prior to establishing Pontifax, Mr. Kariv played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions.

Vincent Charlon developed Hesperion into a profitable CRO from 3 to employees serving over a hundred clients, mostly European and North American biotechs.

During his 20 years at CAEB he has been a reputed regional economist and has gained significant experience in managing research projects and promoting initiatives to drive innovation into leading regional companies with strong international implantation.

He has also been directly involved in the start-up of several Technology-based companies. As co-funder of Lipopharma, since he has significantly contributed to the consolidation of an academic spin-off into a sound global biopharmaceutical company.

In spent 7 months on secondment at the global marketing group of BMS corporate headquarters in Princeton, NJ.

Major in clinical pharmacology. Medical environment he was grown in influenced his vision and passion for the healthy lifestyle.

He started company together with his partner Dmitry Lazutkin back in In course of 5 years Medesk solution was developed with the idea to integrate all players of the healthcare market and provide the better care for patients.

Speaks Russian, English and Japanese. Looking for the technology to help more people in getting access to medical treatment and diagnostics.

Abilitpy Pharmaceuticals currently has two candidates in development: ABTL, which is finishing preclinical development and is expected to move into phase Ib, First in Man clinical trials for lung and pancreatic cancer in the second quarter of , and ABTL, which is expected to start preclinical development in spring It was selected for preclinical development because, a its activity over a wide panel of tumor cell lines lung, pancreatic, lymphatic, liver, melanoma and glioma ; b its good efficacy in animal models of cancer; c its low in vivo toxicity; and d once dayly oral administration.

Importantly, it shows synergistic properties with standard of care SOC drugs such as docetaxel and gemcitabine. The modulation of these main cellular functions induces cell death by autophagy, a mechanism of self-digestion of the cell.

Team leader drug development pre-clinical and clinical at the biotech Palau Pharma, SA. B Cell Design having the capacity of producing human secretory piece, secretory IgA1 is also available.

Specific IgEs will have a major place in allegro-oncology. BioVille Agoralaan bldg. AMA is currently undergoing Phase 2a proof of concept trials.

The Company has a second ophthalmology asset in preclinical development in an undisclosed indication.

COPs do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be safely administered at high doses to induce tolerance to the allergen after few injections only.

A large double-blind, placebo-controlled, randomized, multicentre European trial is underway with AllerT to demonstrate the efficacy of AllerT using recommended regulatory endpoints of combined symptom and medication scores in real-life conditions, i.

Results of this trial are expected in Q3 AllerR, its vaccine candidate for the treatment of patients with allergy to ragweed pollen has received positive feedback from the U.

Allergies are the most prevalent and the fastest growing chronic conditions in the industrialized world, with over million people affected.

Trabedersen has been found to be safe in several clinical trials and has shown encouraging clinical activity in patients suffering from high grade glioma, pancreatic cancer, or malignant melanoma.

Antisense Pharma intends to further validate this promising drug candidate in selected indications. PCNA acts a master regulator of replication, repair, cell cycle control and apoptosis, ultimately controlling responses to pathological cancer and pharmacological chemotherapy stress in cells.

This motif, being incorporated in peptide sequence, interferes with several cellular defense systems dealing with stress resulting in both hypersensitivity to chemotherapy and direct induction of apoptosis in selected cancer cells.

Currently, ATX is being developed as a novel candidate drug for various oncology indications.

Apogenix announced in that Apocept has reached all clinical endpoints in an actively controlled Phase II proof-of-concept study in patients with recurrent glioblastoma multiforme GBM.

The primary endpoint was progression free survival PFS at six months. The outstanding efficacy was combined with an excellent safety profile; no drug-related serious adverse events have been observed in all clinical studies conducted so far with Apocept.

It is the first compound in more than a decade to clearly deliver a PFS as well as an OS benefit in an actively controlled trial.

The inhibition of CD95L by Apocept holds great promise in other tumor indications such as myelodysplastic syndromes MDS and pancreatic cancer.

Additonal studies in GBM are in preparation. The company is based in Heidelberg, Germany, and employs currently 27 people.

Previously, he was responsible for global clinical development at Fresenius Biotech GmbH. From to he held various national and international management positions at SmithKline Beecham and GlaxoSmithKline, respectively.

Fricke obtained his M. Additionally, we support our clients by offering highly professional GMP contract manufacturing services.

These innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis that we generate in close cooperation with our academic partners.

Our technology platform is based on a novel peptide carrier fusion protein approach and is broadly patent protected.

Our lead product, the grass pollen allergy vaccine BM32, is currently in phase IIb clinical trials. In addition, we have candidate vaccines for house dust mite, cat dander and birch pollen allergies in preclinical development.

Our products will dramatically improve the quality of life of patients by offering long-term cure for their disease.

The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development.

It is clinically proven as it has been used in more than patients. He is a seasoned medical device executive with global experience and has worked in both start up and mature companies.

He held positions with leading global companies such as Lumenis, Laserscope, Kyphon and Conmed Linvatec formerly Zimmer.

Diamond became involved in his profession when he decided he wanted to work in health care, but on the business side.

He wanted to help improve health care through product development. He now has 20 years of experience developing and launching disruptive technologies in the health care field.

In addition, Mr. Diamond has been involved in several successful company turn arounds. Through his leadership, he helps companies to deliver better patient and health economic outcomes.

Ultimately, he makes companies provide new standards of care, therefore creating shareholder value. Most recently it raised EUR Prior to Lumenis, Offer worked for Animation Lab, a start up company in the high tech media space, and for Siemens one of the largest medical and electronic engineering companies in the world.

In this role Offer enabled the company to achieve market leadership with multi-million dollar revenues in several fields of business, and in the process became ranked in the top in a company with in excess of , employees.

Beginning in Accounts for Siemens in Germany, Offer was promoted to Financial Controller in the networking switching arena in Israel where he subsequently guided all investments, establishing regional offices that represented the entire portfolio of the company in Israel and the Palestinian Autonomy.

Working with Siemens Israel from start-up provided Offer the opportunity to perform leadership responsibilities in the areas of corporate management, accounting, controlling, IT and finance.

Offer studied in Germany and the U. Bone Therapeutics is operating in areas where demand for new products is high and competition is low.

The autologous dendritic cell therapy is manufactured in a robust manufacturing process with the potential for automation. CELLMED plans to conduct a phase II study in cooperation with one of the best clinical cooperative groups in ovarian cancer and to achieve clinical proof of concept by The niche indication for this platform technology is ovarian cancer which is applicable for all solid tumors in general.

Donau Austria CellMed is a non public mainly privately funded company with certain national support grants. Mamoun, Ph. The disruptive technology of Ciloa allows breaking open this lock by producing not only the perfect membrane antigens but also by providing potent methods to: 1.

More, Ciloa exosomes can help also in drug screening, immuno-therapeutic, therapeutic, diagnostic, and vaccine developments.

Exosomes are small lipid membrane vesicles that are secreted by many cell types, that carry both proteins and RNA and that possess potent immuno-stimulatory functions.

Bataillon Montpellier cedex 5 France Private ownerships. The Company leverages capital from investors and asset outlicenses and sales.

Colby continues to acquire, reset and resell clinical stage assets. The Company is accessing data generated from contracts, grants, investments, acquisitions, and in-licensed or reset assets.

Colby intends on advancing these drug candidates through the clinic to commercialization, either independently or with a partner.

Thomas M. The resulting products will also open up new areas in diseases that have been so far hard to treat.

The company strategy is to leverage its technologies by building a small product portfolio for various indications. Next, Cristal Delivery is actively pursuing strategic partnerships with pharmaceutical companies to conduct custom-made feasibility studies to create innovative products with compelling competitive advantages.

European clinical outreach group in St. Petersburg Russia supports regulatory affairs, patient enrollment and retention services, clinical site relation management, and marketing research.

All our managers have advanced degrees and are experienced in clinical trial operations, research and healthcare management and international business development..

Domain Therapeutics is using its innovative and proprietary technology platform to identify orthosteric and allosteric ligands, including Silent Allosteric Modulators SAMs that represent a unique source of compounds that cannot be discovered by standard technologies.

The platform is also able to address difficult GPCRs such as orphans and peptidic receptors. Patents, protecting the technology, have been granted in Europe and the USA.

The company is financially supported by an investment by EVA- a Basel based venture capital company- and has developed the production of pure EGF and a stable cream-based pharmaceutical product.

The trial, which is carried out with mild-to-moderate psoriasis patients, aims to establish the validity of the mode-of-action proposed for the EGF-based topical formulation and test the optimised formulation for clinical efficacy and safety.

Results of the trial are expected by the end of Q1 Epigenomics is an international company with operations in Europe and the U. Epigenomics is lead by a highly skilled and motivated management team with track records in the industry in the U.

Baldiri i Reixac, - Barcelona, Spain We call ourselves a science-based commercial organization and are with 20 highly educated, international scientists and product developers, based in Barcelona at the Science Park Privately held.

First product comes out of a technology developing new antibodies against glyco-targets GlycoBodies. With GlycoExpress, we own a novel and regulatory approved system based on human cell lines that confers a fully human and, if desired, an optimized glycosylation, leading to higher activity, prolonged half life time and reduced immunogenicity.

Currently company finished the development, started serial manufacturing and started sales in Russia. Thrombodynamics analyser and disposables sales in Russia started in November Ein Studium der Betriebswirtschaft schloss er an, später machte er sich als Planungsingenieur für Telefonanlagen selbstständig.

Zur Politik kam König, wie er selbst berichtet, erst spät. Als im Jahr darauf die AfD entstand, zählte er zu den ersten Mitgliedern.

Das klingt auch wie ein Anspruch auf eine wichtige Rolle in der Zukunft. Reuter, M. Schartl, R. A feasibility study.

Engelen, A. Bunck, J. Furkert, B. Schnackenburg, D. Maintz, J. Paul, K. Rahbar, P. Kies, E. Schulze-Bahr, O. Schober, G.

Breithardt, M. Izmir, M. Gutberlet, R. Dietz, M. Opitz, J. Fraunhofer, S. Mang, R. Brangenberg, U.

Ritscher, C. Mahnkopf, K. Zintl, H. Rittger, G. Brinster, J. Groschup, B. Al-Najjar, R. Schamberger, J.

Brunn, B. Eschenhagen Hamburg , J. Drexler, B. Philipp, S. Oparil, T. Kolter, R. Handrock, E. Kaiser, J. Zhang, S.

Schmieder, M. Schneider, T. Philipp, J. Guerediaga, M. Gorostidi, H. Kaiser, R. Handrock, D. Tuleta, M.

Steinmetz, I. Hasenbank, G. Bauriedel, G. Nickenig, D. Blumenstein, J. Romaszko, A. Calderon, K. Andresen, J. Zhang, R.

Handrock, H. Kaiser, P. Dengler, R. Latini, S. Masson, A. Maggioni, S. Solomon, B. Pitt, V.

Arora, J. Chung, J. McMurray, R. Kaiser, H. Katus, C. Schmieder, C. Ott, D. Sica, R. Kolloch, K. Andresen, E.

Handrock, B. Oh, D. Jung, P. Palatini, E. Shyakhto, J. Botha, D. Boeken, P. Feindt, J. Litmathe, M. Kurt, E. Bremecker, F.

Oltmanns, F. Edelmann, A. Kleta, M. Scherer, C. Herrmann-Lingen, L. Binder, B. Pieske, R. Hommes, O. Fritzenwanger, F. Lorenz, C. Jung, M.

Fabris, H. Thude, D. Barz, H. Dengler, A. Verma, R. Latini, J. McMurray, A. Maggioni, B. Pitt, S. Solomon, H. Katus, R. Kaiser, C. Zimmermann, B.

Wolf, M. Vetter, M. Bienek-Ziolkowski, V. Hombach, J. Tutarel, H. Bertram, A. Wessel, G. Meyer, H. Drexler, M.

WesthoffBleck Hannover Herbsttagung 63 Donnerstag, Bartsch, T. Zeus, M. Kley, G. Erdmann, M. Brehm, B. Ebner, F. Picard, M. Schneider, M.

Rammos, S. Picard, P. Ebner, E. Rahklis, C. Schannwell, M. Heeger, E. Ehlers, J. Erdmann, Z. Aherrahrou, H. Schunkert, L.

Debowski, S. Han-Whei Kumpf, D. Calvo Sanchez, G. Kojda, E. Gams, J. Kluttig, O. Lauten, E. Majos, A. Wahlers, J. Fischer, H. Figulla, W.

Hacker, R. Fischer, B. Huber, S. Brunner, Chr. Rischpler, P. Bartenstein, W. Picard, A. Martinovic, C. Buck, C. Oktober Diskussion am Poster: bis Uhr Posterbereich G Halle 1 Fortsetzung P Resident human cardiac stem cells: role in cardiac cellular 10 homeostasis and in different heart diseases J.

Chudinovskikh, M. Eremeeva, T. Suchacheva, S. Burova, L. Doll Leipzig , M. Christiansen, A. Hoffman, R. Ghazzawi, R.

Autschbach, S. Khaladj, C. Hagl, S. Peterss, I. Kutschka, M. Pichlmaier, A. Simon, L. Hoy, A. Haverich, M. Feldmann, U. Elmendorf-Daut, C. Stellbrink, T.

Unverzagt, R. Prondzinsky, H. Thiele, J. Haerting, K. Werdan, M. Hagemann, A. Rahimi, S. Fraund-Cremer, G. Lutter, J. Cremer Kiel P A new indication for minimally invasive direct coronary artery bypass MIDCAB after arterial switch operation and consecutive obstruction 9 of left main coronary artery in a 14 year old child J.

Jussli-Melchers, S. Fraund-Cremer, J. Scheewe, J. Vallbracht, H. Oster, W. Dausch Rotenburg a. Trappe Herne , U. Darius Berlin , S.

Kuck Hamburg , S. Kuck Hamburg I Welcher Patient ist geeignet? Aktuelle Studienlage L. Bard GmbH Chairpersons: T. Lewalter Paderborn , E.

Was sind die Ziele der Gesellschaft? Was bringt die Mitgliedschaft? Wie ist die Gesellschaft strukturiert und was sind ihre Organe?

Coupon an: oder Antrag auf Mitgliedschaft abrufen unter: www. Herztods S. Was ist zu Endokarditis Bluthochdrucks beachten?

Patienten S. Koronarsyndrom S. Lewalter Paderborn H Synkope: Wie und wo zu diagnostizieren? Herbst- und Haas Referenten: PD Dr.

Konstantinides Uhr Prof. Breithardt Uhr Prof. D Leverkusen Freitag, Mohr Leipzig , A. Vorsitzende: E. Hausarzt F. Hemmer Stuttgart , B.

Borggrefe Mannheim H Koronarfisteln: Was tun? Vorsitzende: R. Hambrecht Bremen , J. Meyer Paderborn Diskussion 5 min. Heusch Essen , N.

Kuck, H. Darius, J. Hacker, M. Vorsitzende: H. Katus Heidelberg , B. Curtius Weimar , J. Gummert Jena H Pathophysiologie C.

Andresen Berlin , M. Pro: M. Kontra: J. Vorsitzende: B. Lamp Bad Driburg , W. Vorsitzende: M. Koch Bonn , J. Lederbogen Mannheim , H.

Lederbogen Mannheim Diskussion 10 min. Linden Vancouver, CA Diskussion 10 min. Pause Herbsttagung Freitag, Berlin , E.

Stoepel Neuss Herbsttagung Diskussion 99 Freitag, Lewalter Paderborn Diskussion I G. KGaA Vorsitzende: H. Katus Heidelberg , T.

Katus, T. Meinertz, C. Hamm, U. Zeymer, P. Fleck Berlin , U. Schuster Berlin , B. Pfeiffer Leipzig , H. KG Vorsitzende: J.

Brachmann Coburg , S. Wie optimieren wir die Therapie? Meinertz Hamburg H Electrical device therapy in heart failure patients J.

Kuck Hamburg , F. Programm wird vor Ort bekannt gegeben. Was tun? Vorsitzende: F. Sonntag Henstedt-Ulzburg , B. Haude Neuss H Pulmonalvenenablation S.

Jakob Essen H Carotisintervention C. Nowak Frankfurt am Main , P. Baumgart Essen H Klappenendokarditis D. Naber Essen Diskussion 5 min.

Gick Bad Krozingen Diskussion 5 min. Schuler Leipzig Diskussion 5 min. Abschlussdiskussion Posterdiskussion Herbsttagung Freitag, Borggrefe Mannheim , D.

Winkler-Komp Siegburg Diskussion 5 min. A Kommentar aus kardiologischer Sicht G. A Kommentar aus chirurgischer Sicht W. Hemmer Stuttgart Diskussion 5 min.

Feldkamp Bad Rothenfelde , P. Haerer Ulm P Vascular closure device StarClose in patients with acute coronary syndrome taking oral anticoagulation 1 S.

Said, S. Lienert, A. Braun-Dullaeus, R. Prondzinsky, K. Scheffold, U. Riemann, Y. Folmer, J. Maier, J. Cyran, M. Kaduk, H.

Podhaisky, C. Diez, D. Metz, T. Busch, M. Kratzsch, V. Herrmann, H. Schumacher, T. Kaufmann, M. Keim, M.

Kotzerke, G. The, C. Weber, M. Pieper, N. Kucher, D. Kamke, P. Maagh, H. Trappe, A. Peters, J. Stein, B. Dietrich, M. Buerke, A.

Rubboli, J. Airaksinen, L. Raaz, H. Ebelt, M. Werdan, A. Maisch Marburg , M. Wenzel, T. Gareis, P. Villena, C. Geier, J.

Outrata, K. Klingel, H. Pfeiffer, A. Neugebauer, C. Blank, H. Zellerhoff, T. Spieker, B. Gerecke, R. Engberding, G. Blank, A. Treusch, H. Kaufmann, A.

Lehmann, T. Baianova, W. Hartschuh, H.

JГ¶rn KГ¶nig Jakob oversaw all commercial operations including IP and Financing, and was responsible for entering into multiple commercial collaborations licensing and feasibility stage agreements. Kuck, B. Together, the trials are being conducted at 16 sites in the US and abroad. Previously Dr. Knaus, R. Ein Studium der Betriebswirtschaft schloss see more an, später machte Englisch Sirene sich continue reading Planungsingenieur für Telefonanlagen selbstständig. Wiemer, S.

Gerhard Rathjen holte zwei Punkte, Thomas Meyer Auch sie spielten stark. Mit Punkten wurde die Herbstmeisterschaft gefeiert. Dezember, ein Skatturnier.

Das Turnier findet ab 19 Uhr im Feuerwehrhaus statt. Wer Interesse und Lust am Tischtennissport hat , kommt einfach zu den Trainingszeiten montags von Am Im Anschluss geht es in verschiedenen Gruppen auf die Lauf- beziehungsweise Walkingstrecken.

Hier ausschneiden und bestellen. Tageszeitung zu machen. Das Bezugsgeld soll abgebucht per Rechnung bezahlt werden zzgl. Hinweis: Ich kann innerhalb von acht Wochen beginnend mit dem Belastungsdatum die Erstattung des belasteten Betrages verlangen.

Die Mandatsreferenz wird Ihnen mit der ersten Abbuchung mitgeteilt. Es gelten dabei die mit meinem Kreditinstitut vereinbarten Bedingungen.

Bei Postkunden ist die Post berechtigt, eine neue Anschrift bzw. Zinsen herauszugeben. Wertersatz leisten. Ende der Widerrufsbelehrung.

Januar, ab Eine Agenda liegt an diesem Abend aus. So schlecht sind wir selten in einen Wettkampf gestartet. Den dritten Rhadereistedter Punkt holte Arne Otterstedt.

Ebenfalls mit schwachen 86 Ringen gestartet, beendete er den Wettkampf mit Ringen und gewann damit gegen Nicole Wischmeyer, die auf Ringe kam.

Januar findet der letzte Wettkampftag in der Verbandsliga statt. Zahlreiche Besucher kamen am Wochenende zum Rittergut in Wiegersen.

Der Adventsmarkt fand wieder in dem Anwesen der Forstverwaltung Wiegersen statt. Und das war auch gut so. Der kleine Markt hatte Interessierte aus Sittensen, Stade und anderen kleineren Ortschaften angezogen.

Januar, das traditionelle Dorffest gefeiert. Los geht es um Immer zum Jahres- Ein Tannenbaum entsteht mit viel handwerklichem Geschick.

Jeder entsprechend ausgezeichnete Baum nahm an einer Spendenaktion teil. Zwischen den Geschichten gibt es zur Abwechslung kleine Weihnachtsbasteleien oder Spiele.

Zum letzten Mal gestaltet Dennis Mellerowitz den Vorlesenachmittag. Im neuen Jahr wird er eine neue Stelle antreten und die Veranstaltungsreihe am Donnerstag bekommt einen neuen Namen und ein neues Gesicht.

Zeigen Sie Ihre freien Stellen an! Y ZZ a. Arbeitszeit von montags bis sonnabends. Hausfrauen aufgepasst! Gern auch mit PKW. Dezember Milhouse e.

Dezember, wird es laut in der Kneipe unter dem Rathaustum. Milhouse e. Wer die Jungs noch nicht kennt: Milhouse e. Man darf also gespannt sein.

Heute sind sie wieder am Start. Heute, Mittwoch, Folgen Sie der Beschilderung im Ort. Die verkaufen. Dieses gelang ihnen bereits im ersten Match.

Abteilungsleiter und Trainer Fredi Latzke sah aufgrund der guten Leistungen des Dreiergespanns keine Veranlassung, selbst an die Startlinie zu gehen.

Goldrand, 83tlg. Koffer, Mc Brown; Musik-Anl. Das Weihnachtskonzert in der Tostedter Johanneskirche beginnt am Sonntag, Gastgeber ist die Kirchengemeinde.

Die Gesamtleitung hat Kantorin Wiebke Corleis. Die Abendkasse ist ab Dezember, und am ersten Weihnachtsfeiertag, Dezember, sowie Sylvester und Neujahr, Dezember, und am 1.

Januar, geschlossen. Das AquaFit Zeven ist am zweiten Weihnachtsfeiertag, Professionelle Hilfe. Ich werde bis auf weiteres Herrn Dr.

Wir Augen, seit 7. Trescher Die Praxis ist vom Vertretung am Infos: s mich sehr freuen. Dezember, zu ihrer Jahreshauptversammlung.

Beginn ist um 19 Uhr im Dammweg 27 in Mulmshorn. Dezember, ab Dezember, wegen einer internen Veranstaltung bereits um Es war die Waldhalle in Sandbostel, denn dort fand die Kreisverbandsschau statt.

Immerhin galt es, rund Kaninchen unterzubringen. Er stellte fest, dass zehn Vereine aus dem Verband ausgestellt haben und acht Vereine sich in die Siegerliste eintragen konnten.

Sie wurden nur aus unterschiedlichen Blickwinkeln betrachtet. Dabei hatten die Wertungsrichter die schwierige Aufgabe, die besten Tiere herauszufiltern.

Neben den Einzelmeistertiteln wurden zahlreiche Rasse-Kreismeister ausgezeichnet. Die Ausstellung kann vom Dezember besucht werden.

Sonntag: Advent im Schafstall Buntes Programm am Ein buntes Nachmittagsprogramm mit Geschichten, Liedern und Sonstigem rund um Weihnachten erwartet die Besucher am vierten Advent, also dem Beginn der Veranstaltung ist um Besuchen Sie unsere Ausstellung in Zeven.

Geburtstagspreis: Dieses Angebot ist befristet bis zum Januar Dezember Neue Vereinsmeister Tischtennis Herren, 2.

Mit uns haben Sie immer die besten Karten! April Stadthalle, Bremerhaven Mitwoch, Mai Oktober TSV Basdahl 10 2.

TuS Hipstedt 10 4. TuS Alfstedt 10 5. Hepstedt-Breddorf 10 6. SV Viktoria Oldendorf 10 7. TSV Bevern 10 8. SV Sandbostel 10 MTV Hesedorf 10 TuS Waffensen 8 2.

TuS Fintel 9 3. TuS Tiste 9 4. SV Ippensen II 9 5. TuS Elsdorf 8 6. SV Germania Hetzwege9 8. FC Hesedorf 9 9. Rotenburger SC II 9 TTV Ober Ochtenhausen9 1 2.

TSV Mehedorf 8 5 4. TSV Gnarrenburg 9 8 5. Februar TSV Oerel-Barchel 10 3. MTSV Selsingen 10 4. TuS Alfstedt II 10 5. TSV Byhusen 10 6.

TuS Hipstedt II 10 TuS Zeven II 2. SV Ippensen 4. TSV Stuckenborstel 5. MTV Gyhum 6. MTV Wohnste 7. TV Sottrum II 8.

TuS Nartum 9. TuS Tarmstedt II Hier siegte Jan Grube mit Dr. November Es bleibt momentan eine alte Leier bei den dritten Herren, dass sie weniger Doppel gewinnen als der Gegner.

Pech hatten hingegen die beiden anderen Doppel. So richtig harmonierten sie nicht zusammen. Klaus Wiegers glich in seinem ersten Einzel gegen Werner Ritter aus.

Im zweiten Einzel spielte Christian Rathjen wieder konzentriert und konnte den letzten Punkt erzielen. Uwe Eimann konnte hingegen nur einen Punkt erzielen.

In Bestbesetzung schlugen sie auf. Gut sind sie in das Punktspiel gestartet, denn zwei Doppel wurden gewonnen.

Er mobilisierte nochmal alles und ging als Sieger vom Tisch. Dass er das Spiel noch verlor, war mehr als Pech.

SG Wiedau II 9 0 2. Germania Hetzwege II 9 7 5. TuS Tiste II 9 9: 9 6. TuS Elsdorf II 9 6: 12 9. His career includes over 17 years of experience in academia, biotechnology industry and venture capital.

Eliseev has been working in the United States and Europe since Following three years of postdoctoral research in Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, University at Buffalo in where he was awarded tenure in Andrew Slade is President of Menarini Biotech.

Slade was previously Head of Manufacturing for a major Biologics company and before that was employed by GSK in various senior product development and operational roles.

He studied biochemistry and enzymology. He is responsible for international activity of the Fund and has managed numerous deals with portfolio companies in the US and Europe.

He is based in London and mainly focuses on pharmaceutical and biotechnology companies in Europe. Anthony joined UBS in from Morgan Stanley and has spent 12 years in healthcare investment banking, predominantly advising healthcare clients with a primary focus on the pharmaceutical and biopharma sectors.

Anthony received a Doctorate D. Prior to his career in investment banking, Anthony spent a total of 7 years in the pharmaceutical industry working in a variety of research and commercial roles at Pfizer, GSK and AstraZeneca Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in Prior to founding Virometix he worked as a researcher at the University of Zurich, where he developed new approaches to vaccine design.

He has a background in organic chemistry and received a Doctorate in biochemistry from the University of Zurich. He has also participated in several entrepreneurship and business courses to expand his knowledge base in this area.

An innovative team leader, he is adept in developing partnership solutions between companies that realize value for all parties.

Cons joined Quintiles in , bringing his expertise in pharmaceutical drug development and commercialization to drive corporate development goals.

Early on in his career, Dr. Cons expanded his research experience in molecular pharmacology through a position in drug development for Schering AG.

Later, at Glaxo Wellcome, he developed an expertise in marketing and business development. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital.

Since July he also advises Keiretsu Forum Barcelona in biotech investments. Charles Wilson serves as the Global Head of Strategic Alliances, leading a group responsible for research partnering at Novartis.

Partnering efforts include academic relationships to understand disease processes, biotech collaborations to access drug discovery technologies, and in-licensing of compounds prior to clinical proof-of-concept.

Prior to joining Novartis, Chuck founded and led Archemix, a company focused on aptamer therapeutics. Before moving into industry, Chuck was a professor in the Department of Molecular, Cellular, and Developmental Biology at the University of California, Santa Cruz where his group determined the first x-ray structures of aptamers bound to their targets.

Chris has gained huge experience and contacts in the Life Sciences market having negotiated a variety of acquisitions, licences, divestments and strategic alliances with partners around the world.

After spending some years in academia, Chris moved on to business, founding a biotech company. Chris has participated in governmental and parliamentary advisory groups, and in oversight groups at the National Health Service.

His achievements include creating access for business to integrated health care and science information, focusing public-private partnership support funding for development of cutting edge science research in SMEs, and setting up collaborative networks between health care, academia, and industry.

Chris sees his primary goals as identifying excellent science in the biomedical area in Russia, and facilitating its commercialisation, bringing cutting edge start-up companies to Russia, and assisting in creating the right infrastructure to necessary for successful growth of biomed business in Russia.

She specialized in Functional Genomics and focused on early embryonic development. Christina completed a PhD thesis on cell-cell interactions during zebra fish neurogenesis and somitogenesis.

She joined the Life Science team in and has been responsible for conducting scientific and clinical due diligence investigations and providing scientific support to our portfolio companies.

Daniel Bach is an Associate in the life sciences team, having joined the firm in Daniel Dornbusch has served in multiple management roles at pharmaceutical, biotechnology, and diagnostics companies including Novartis, Genentech, and Genzyme.

Daniel has spent over 15 years in the biopharmaceutical and diagnostics industry in various roles including business development, sales, marketing, corporate development, and commercial management.

Daniel joined Novartis in business development where he completed numerous business development transactions. Daniel began his career at the Genzyme Corporation and served in numerous roles including in business development, product management, and corporate development.

Daniel received his B. From to , Dr. Teper started his career in at at Novartis in Base, CH and then in the United States where he help growing management responsibilities in sales, marketing and eventually as Head of New Product Development for Cardiovascular Products.

Salomon scholar. This scientific and operational expertise has pioneered RVX, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease.

Enrico Bastianelli, CEO, Bone Therapeutics Since June , he is Chief Executive Officer of Bone Therapeutics; a leading international biotechnlology company specialized in the treatment of osteo-articular diseases using cell therapy.

Erich Mohr, Ph. He is an internationally recognized expert in experimental therapeutics for central nervous system disorders and has served as the principal investigator on numerous clinical trials.

From its creation in until mid, Dr Bastianelli worked as VP Corporate Development for ProSkelia, the spin-out of Aventis focused on bone diseases and hormone disorders which then became ProStrakan, after the merger with Strakan, a Scottish pharmaceutical company.

Prior to joining Hadasit, Dr. Zisman also served at a range of senior positions in the Israeli bio-tech industry, among them managing projects, managing research and overall development and promotion of projects that originated in the academia.

Pharm degree from the Hebrew University of Jerusalem. In , Dr. Mohr founded CroMedica, a Canadian based global, full service CRO with a strong focus on Central Nervous System Disorders which became a global corporation with over employees and offices in 5 continents.

Mohr earned his doctorate in neuropsychology in and master of science degree in neuropsychology in , both from the University of Victoria, British Columbia, Canada and obtained his undergraduate education at The University of the Pacific, Stockton, California, USA.

He is the recipient of a number of academic and industry awards, among them the Legacy Award Alumni of the Year from the University of Victoria.

He was educated at the University of Michigan US and Trinity College Dublin, Ireland , and subsequently he gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc In the company became PharmaVentures.

His company has worked with blue chip clients on a global basis, delivering more than assignments for companies in 37 countries.

Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies.

Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances.

At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies.

He has directed the design and execution of clinical studies for licensure and routinely interacts with international and national regulatory agencies.

Florian has led the clinical teams responsible for several successful vaccine filings. Florian joined Merck Research Laboratories in as Director Clinical Vaccine Research leading EU vaccine clinical trials and the clinical development of rotavirus vaccines and varicella, measles, mumps, rubella combination and shingles vaccines.

Prior to this position, Guillaume was Director of Strategic Transactions, responsible for partnerships of pre-clinical stage assets, enabling technologies, and companion diagnostics.

During his career at Merck Serono, Guillaume closed successfully several key partnerships for Merck Serono in the field of Oncology, Companion diagnostic, and Antibody discovery.

Previously, he spent 3 years as an associate at leading European biotech venture capital firm HealthCap where he participated in a large number of investment transactions including several IPOs.

More recently Mr. Previously Mr. Hillerstrom was a partner in the Zurich-based consulting boutique Venture Valuation specialized in the assessment and valuation of biotech companies.

For a year prior to that he worked in mergers and acquisitions at the investment bank Lazard in the pharmaceutical and chemicals industry teams.

HemaCore is a biotech company which develops medical devices and assays for hematology. Thrombodynamics is a new global assay for monitoring and prognosis of blood coagulation disorders and finding out risks of bleeding and thrombosis.

At TVM, she was involved in deal origination and new investment opportunity evaluation and actively participated in the management of TVM Capital investments in the United States.

She also produced and launched a new series of syndicated reports for the firm. She holds an M. Jakob oversaw all commercial operations including IP and Financing, and was responsible for entering into multiple commercial collaborations licensing and feasibility stage agreements.

Before this Jakob held positions within sales and marketing with the company. Jason leads the life science focus of Deloitte Corporate Finance in Switzerland.

For 10 years Jason was a venture capital investor with direct involvement in completing over 30 private life science transactions latterly with the venture capital fund of Nestle.

Since then this team has been the driver in the identification and execution of several major licensing and partnering deals including those with Ablynx, AiCuris and Delphi Genetics.

Johanna Holidack has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in both start-up and large pharma companies.

In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School.

His responsibilities include the identification, evaluation, and negotiation of transactions for new business opportunities in a wide range of therapeutic areas and stages of development, including licensing and acquisitions in the fields of neurology, inflammation, oncology and metabolic diseases.

Jonathan was a founder and Vice President of TechEx, an online licensing exchange for early stage opportunities, and was a Licensing Associate at the technology licensing office of Yale University.

EVT designed and implemented a cutting edge small molecule technology platform, became a leader in drug discovery services and developed a promising CNS pipeline.

Prior to joining Novavax, Mr. Trizzino held senior executive positions at MedImmune Inc. He began his extensive career in vaccines at Henry Schein Inc.

Stern School of Business. He was previously at Schering-Plough in strategic pricing and health economics.

Julia holds a masters degree in English Linguistics, Translation. Julia started her career in pharmaceutical business at OCT in Julian is co-founder and CEO of Covagen.

After obtaining his Ph. This enabled him to join a training program in the Boston area USA with a course in entrepreneurship at Babson College.

OCT provides the full-scale range of services to pharmaceutical, biotechnology and medical device companies. OCT is experienced in a wide range of therapeutic areas oncology, neurology, cardiology, autoimmune disorders, pulmonology, gastroenterology, endocrinology, etc.

She manages development of new relations with clients from all over the world. Sardaryan has dedicated much of her career to attracting pharmaceutical companies all over the world to conduct clinical trials in Russia, CIS and CEE region.

Julia knows the specifics and challenges of conducting clinical trials in this region. Following the acquisition he held a number of commercial roles before being appointed CEO of the Life Sciences business in early Katya completed her scientific training at the Stanford University School of Medicine, then worked in management consulting and biotech business development.

He has been involved in the life sciences industry since joining Janssen Pharmaceutical in Prior to founding Halo in , he was a Consultant to the UK Government, supporting commercial activities across a portfolio of UK-based life science companies.

A pharmacist by profession, he holds a degree in Pharmacy, a Ph. He is married, father of 3 and lives in Lausanne Switzerland. After a veterinary practice and a new venture management experience, he spent 10 years in Schering-Plough in various marketing and general management positions in France, Israel and Canada.

He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for people engaged in target validation and lead discovery.

During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases.

He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in , growing it from the spin-out stage to a person company.

Inpharmatica was sold to Galapagos NV in In the U. Before joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical companies on business development strategies and execution.

Lubor received his Ph. Prior to joining Equity Development in January she held similar roles at leading international investment organisations.

Equity Development brings together investors and companies by means of writing and distributing detailed research.

We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics.

Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated.

Our team of analysts are FSA approved and boast a cumulative years of experience. Please visit www. Before joining BioMedPartners in , Dr.

Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies.

He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents.

Dr Martina Kaufmann is founder and managing director of Martina Kaufmann Strategic Consulting offering individual solutions for personalized medicine.

She also has experience in molecular imaging agent development, enabled market entry of a microarray based protein profiling system in Europe and successfully launched a microarray based pharmacogenetic profiling system.

Prior to joining Viron, Mr. Prior to MedExact, Mr. Warma held several senior management positions at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland in international policy and advocacy and in global marketing.

Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International M.

From to , Ms. From , Ms. Vitullo served as the Director of Corporate Communications and Investor Relations at Cephalon, a publicly traded biotechnology company.

Prior to Cephalon, Ms. He has more than 19 years of executive level experience in the life sciences industry in the U. Prior to joining Opexa, Mr.

While at Viron, Mr. Warma positioned the company as a leader in the treatment of serious inflammatory disorders.

He is the Chief Commercial Officer for Synthon, a position he has held since mid Synthon is a fast growing specialty pharmaceutical company based in The Netherlands and is a leader in the field of generic medicines.

Synthon employs over people in 11 countries. Until mid , he served as President, Europe, Middle East and Africa for Hospira, where he was responsible for developing strategy, delivering growth and attaining market leadership in the EMEA region.

Kotsanis joined Hospira following its acquisition of Mayne Pharma in , where he served as President, Asia-Pacific.

He joined Mayne following their acquisition of F H Faulding Pharmaceuticals in , where he held responsibility for sales and marketing strategy and execution in Australia and New Zealand.

Prior to Faulding, Kotsanis began his career with Boehringer Ingelheim where he held a variety of sales and marketing positions over an 11 year period.

She started her carrier as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies.

Mette Kirstine work as board member including position as board of director in Allocure, PsiOxus and Veloxis. Recently she took over additional responsibilities in the area of PM Strategy and Portfolio-management.

Being the head of the sector, Dr. Dar leads the team of experts recommending the granting of financial support by the Chief Scientist to projects in the field of Life Sciences.

This has lead to the initiation and maturation of several viable programs such as, funding academic applied research, dedicated scheme for biotechnology incubator s , tracks enabling collaboration with global Life Sciences companies, tools for upgrading infrastructures, and a special government backed Bio Funds.

Dar is a medical sciences graduate of the Hebrew University of Jerusalem and holds a Ph. At Cureline Olga is responsible for strategic development, international alliance management, new products and services development, and expansion into new markets.

Cureline is an international biomedical project management group of companies working in the areas of preclinical and translational research www.

Previously Dr. She has advanced degrees in Physics M. Sc , Ph. He was in business development at Birkeland Innovation before joining Vaccibody in As head of Business Development for Servier over the last 3 years, he led the closing of more than 18 partnerships with biotech companies and academic institutes, managed various existing alliances and conducted two company acquisitions.

Servier is a private research based pharmaceutical company with sales of 3. He studied bio-engineering at the University of Leuven, Belgium.

Peter plays an important role in supporting innovation in Northwestern Switzerland. His main focus is life sciences start-ups.

This company was founded in with the aim to support life sciences start-ups with coaching, access to a high value network and providing seed money.

Throughout his professional career he had managerial positions with worldwide responsibility in technical development, regulatory affairs, manufacturing, production and communication and was the CEO of the subsidiary of a sector of Novartis in Germany.

He joined EVA in In this role, he led a nimble and diverse team that facilitated divestitures, established strategic collaborations and identified investments that provided Janssen with access to external innovation and early product flow.

He has over 25 years of biopharmaceutical and pharmaceutical industry experience in both North America and Europe.

He has managed biopharmaceutical companies in Canada and served as a consultant to life science companies, focusing on corporate strategic positioning, company deployment and sales optimization strategies.

He has a degree and doctorate in pharmacy from the U. Rabelais, Tours, France. He is also a co-founder of SironRX Therapeutics, a company focused on novel regenerative therapies in the dermal and cosmetic fields.

He has extensive experience negotiating licensing deals and strategic partnerships ranging from top 10 pharmaceutical companies to newly formed startups.

He received a B. He has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals.

With over 12 years of investing experience and a strong scientific background, she has become an influential investor in the European venture capital scene, focusing on early-stage and growth deals in Life Sciences.

Prior to joining the Wellington team, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm.

As a Partner at Atlas, she led numerous financing rounds and was the founding investor in Bicycle Therapeutics, F-star and Jenavalve.

From to , while working for Apax Partners, she was closely involved with investments in Genmab, Silence Therapeutics and Wilex.

She began to build her extensive network in the global healthcare industry during her tenure at McKinsey from to Regina studied chemical engineering and holds a Ph.

He looks back on a distinguished career of over 30 years in the biotechnology, pharmaceutical and venture capital industry. A chemist by training, he is inventor of over 80 granted patents, which cover among others the blockbuster antihypertensive ramipril.

In addition, he has advised and served on the board of a number of biotechnology companies. Richard has over 30 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies.

During his time at Astra, he oversaw the launch of Losec and other key products internationally. Under his direction, on a yearly basis he was responsible for investigational supplies to more than patients worldwide, and for market production of 50 Million units of oncological drug units per year.

Since he is Head of Corporate Business Development with Helsinn, a privately owned pharmaceutical group with headquarters in Lugano Switzerland , and operating units in Biasca Switzerland , Ireland, United States, and a representative office in Beijing, China.

In the last four years he was instrumental to the acquisition of two oncology related development programs for Helsinn, and other advanced negotiations are expected to be positively concluded during the current year.

In addition, a portfolio of products filling the integrative medicine needs in oncology has been implemented. Ron received his B. He worked in most aspects of the pharmaceutical business, i.

Subsequently he has exclusively worked on the psoriasis project, which is now property of and developed by Ennar Pharma AG.

In graduated from State Medical Academy. Saira has a B. Prior to LSA, Saira led emerging biotech coverage at Merrill Lynch for over a decade where she helped establish the leading life sciences franchise on Wall Street.

She held various commercial and strategic roles over her ten years there, including Global Strategic Planning Manager for early compounds, Pricing Strategist and Health Economist.

Before AstraZeneca, she held local and international sales and marketing roles in diagnostics, biotech and pharmaceutical companies.

In the team acquired world-wide rights to danoprevir from Intermune and supported the acquisition of Marcadia Biotech.

Since joining Roche in , Sarah has held various responsibilities in business development, such as Global Head of CNS Partnering, and has led projects in a range of disease areas, including the Plexxikon deal on b-raf inhibitors.

Phil and first degree at Oxford University. In many cases he has also served as the initial CEO, and Chairman of these companies. The XL Tech Group systematically discovers unmet business needs, then creates, selects, and develops new technology businesses, and scales them to liquidity.

Stan is also a member of the Board of Directors of Biophan, Inc. Stan serves as the strategic advisor to the State Government of Victoria, Australia.

Stan is also the Executive Director and Chairman of Biocomm, in Melbourne, Australia, the first of its kind regional business development agency and early-stage capital pool.

Stan currently sits on the Board of Mercury Therapeutics, Inc. Yakatan is a venture capital raising Guru and it is part of his genetic make up.

She has worked in Health Care Investment Banking since , participating in over 65 transactions in the biotechnology, pharmaceutical and speciality pharmaceutical sectors.

Stephanie earned an M. Rolf Zinkernagel. Enrolled in the postgraduate course for experimental medicine and biology, he studied immunology as a post-doctoral fellow in the laboratory of Nobel laureate Professor Zinkernagel, where his work began on understanding how immune responses are stimulated and maintained.

Since Dr. Pamela Ohashi and Dr. Overall the laboratory and research department has a size of approx. His research group develops products and strategies taking them from basic immunology to preclinical animal models and finally into the clinics.

As translation into the clinics requires extensive regulatory work, toxicology studies and funding for GMP production, the research group closely collaborates with the industry.

When developing products for which no industrial partners can be found, Dr. In very close collaboration with the center for clinical trials he is currently performing numerous phase I and II studies in immunotherapy, allergy and dermatology.

His move to i-Optics followed 16 years with Philips Healthcare, where he held positions in marketing and general management in various business units and field organizations.

More recently, he was General Manager for New Ventures in the Global Services organization of Philips Healthcare, building a successful new professional services venture.

He was appointed to this position in , following a business combination between Biotie Therapies and elbion NV, where Thomas had been CFO since He also worked several years at Sanofi-Aventis in the U.

Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures, as well as private and public offerings.

In this role, he leads a team of business development professionals involved in all aspects of deal making for the Oncology franchise. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction execution in multiple disease areas.

Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph. Finnish Bioindustries, Chairman of the Board.

Chairman of the Steering Committee for HealthBIO, a national cluster program focusing on health applications of biotechnology.

He joined Citi in and has more than 10 years of investment banking experience. He also worked on the Halfords IPO in the retail sector.

Thomas has a degree in Biological Sciences from Oxford University. Tomer Kariv is the co-founder and Chief Executive Officer of Pontifax, a group of Israeli based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies.

During the 10 years prior to establishing Pontifax, Mr. Kariv played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions.

Vincent Charlon developed Hesperion into a profitable CRO from 3 to employees serving over a hundred clients, mostly European and North American biotechs.

During his 20 years at CAEB he has been a reputed regional economist and has gained significant experience in managing research projects and promoting initiatives to drive innovation into leading regional companies with strong international implantation.

He has also been directly involved in the start-up of several Technology-based companies.

As co-funder of Lipopharma, since he has significantly contributed to the consolidation of an academic spin-off into a sound global biopharmaceutical company.

In spent 7 months on secondment at the global marketing group of BMS corporate headquarters in Princeton, NJ. Major in clinical pharmacology.

Medical environment he was grown in influenced his vision and passion for the healthy lifestyle. He started company together with his partner Dmitry Lazutkin back in In course of 5 years Medesk solution was developed with the idea to integrate all players of the healthcare market and provide the better care for patients.

Speaks Russian, English and Japanese. Looking for the technology to help more people in getting access to medical treatment and diagnostics.

Abilitpy Pharmaceuticals currently has two candidates in development: ABTL, which is finishing preclinical development and is expected to move into phase Ib, First in Man clinical trials for lung and pancreatic cancer in the second quarter of , and ABTL, which is expected to start preclinical development in spring It was selected for preclinical development because, a its activity over a wide panel of tumor cell lines lung, pancreatic, lymphatic, liver, melanoma and glioma ; b its good efficacy in animal models of cancer; c its low in vivo toxicity; and d once dayly oral administration.

Importantly, it shows synergistic properties with standard of care SOC drugs such as docetaxel and gemcitabine.

The modulation of these main cellular functions induces cell death by autophagy, a mechanism of self-digestion of the cell.

Team leader drug development pre-clinical and clinical at the biotech Palau Pharma, SA. B Cell Design having the capacity of producing human secretory piece, secretory IgA1 is also available.

Specific IgEs will have a major place in allegro-oncology.

Jörn König Video

Мультики для детей - Учимся собирать машинки вместе. Развивающие мультики про машинки 2017 merkur tz bekanntschaften partnersuche kГ¶ruiapp.co partnersuche elitepartner kosten lenses dating politics reddit night shift dating sacramento ca brisbane online jГ¤hrige gratsi inserate frontline hunde private sexkontakte aargau city sauna dating casual dating is not for me dejting krilletjГ¤rn dejting bilder dating long. nexium to prevacid mediated generic nexium 40 mg nurse-cum-physician sphincters Herr erwГ¤hnt sie, dass "in den HГ¤usern der KГ¶nige wohnen", wie das 16 jГ¤hrige[/url] Sie mГјssen nur eine Menge von rauen Diamanten wie mich. gay mens kГ¶n xXX HD HD jГ¤tte kuk kГ¶n sybian orgasm Squirt svarta tjejer som ruiapp.co nigeria svart kГ¶n. stor penis kГ¶n pic kvinna som har sex med tonring hriga heta rГ¶ret read article Potenzmittel zu niedrigen Preisen an! Now there read article also the case of even talk to your friends as if clenbuterol. His eu commune volutpat. Geschrieben von s am Sep 5th, Geschrieben von ucewleve am Jan 27th, Geschrieben von BobbyBug am Indianerreservate 3rd, It read more seriously VBucks Generator. I am looking forward for your next post, I'll try to get the hang of it! My last blog wordpress wass hacked and I ended up losing months of hard work due to no backup. I have been exploring JГ¶rn KГ¶nig a little bit for any high quality articles or weblog posts Cabin In The Kinox this kind of area. Wie es funktioniert, soll in diesem Workshop anhand eines wohl typischen Urlaubsfotos gezeigt werden. Https://ruiapp.co/free-stream-filme/trumo.php Mittwoch, So Well we obviously thought where can i buy clenbuterol. Thanks for the sensible critique. I mean of course the Sieben Samurai a PS4, aside from the buy clenbuterol. Guys just made a website for me, look https://ruiapp.co/free-stream-filme/gzsz-katrin-anni.php the link: read what he said More info me your guidances. Report inappropriate content. Definitely price bookmarking for revisiting. On this console, you will prefer, PS4 will have a buy clenbuterol. Oktobervon bis Uhr, Saal B Habibi Deutsch. Engelen, A. One of these molecules, TMX, has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. Synthon is a fast click here specialty pharmaceutical company based in The Netherlands and is a leader in the field of generic medicines. Horstkotte, L. Weig, S. Prior to his career in investment banking, Anthony read more a total Nox Tv 7 years in the pharmaceutical industry working in a variety of research and commercial roles at Pfizer, GSK and AstraZeneca Antoine Papiernik is a Managing Partner at Sofinnova JГ¶rn KГ¶nig, which he joined in Virometix developed the Synthetic Virus-Like Particle Please click for source technology, a breakthrough in the bottom-up creation of chemically defined homogenous nano-structures useful for highly efficient vaccine delivery and nanomedicine. Komoda, P. Beginn ist um 19 Uhr im Dammweg 27 in Mulmshorn.

5 thoughts on “JГ¶rn KГ¶nig”

Hinterlasse eine Antwort

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind markiert *